GLP-1 (Glucagon-Like Peptide-1) medications are a type of prescription drug that have been gaining attention in the medical community for their potential benefits in managing various health conditions, particularly for women with Polycystic Ovary Syndrome (PCOS)
Retatrutide significantly reduced body weight (mean difference [MD]: 14.33%), body mass index (MD: 5.38), waist circumference (MD: 10.51 cm), fasting plasma glucose (MD: 23.51 mg/dL), hemoglobin A1c (MD: 0.91%), and systolic and diastolic blood pressure (MD: 9.88 mm Hg and 3.88 mm Hg, respectively), all with P values 35 kg/m 2 , frequently resulting in diabetes remission and improvement in associated obesity-related conditions
The names of the 74 candidate biomarkers identified, their direction of variation in the different biological compartments studied and the cohort sizes of the selected articles are detailed in Table 1
How This Compares to Retatrutide's Cardiovascular Benefits The 57 bpm heart rate increase exists alongside substantial cardiovascular improvements: From TRIUMPH-4 Phase 3 data: systolic blood pressure fell by 14.0 mmHg at 12mg